tradingkey.logo
tradingkey.logo
Search

AC Immune SA

ACIU
Add to Watchlist
2.130USD
-0.010-0.47%
Close 11-13 16:00(ET)
216.77MMarket Cap
LossP/E TTM

About AC Immune SA Company

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

AC Immune SA Profile

Ticker SymbolACIU
Company nameAC Immune SA
IPO dateSep 23, 2016
CEOPfeifer (Andrea)
Number of employees133
Security typeOrdinary Share
Fiscal year-endSep 23
AddressEPFL Innovation Park
CityLAUSANNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code1015
Phone41213459121
Websitehttps://www.acimmune.com/
Ticker SymbolACIU
IPO dateSep 23, 2016
CEOPfeifer (Andrea)

Company Executives of AC Immune SA

Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
75.27K
+22.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
74.24K
+38.31%
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
71.66K
+24.77%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
64.52K
+36.77%
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Martin Zugel, M.D.
Mr. Martin Zugel, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Renee Aguiar-Lucander
Ms. Renee Aguiar-Lucander
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
75.27K
+22.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
74.24K
+38.31%
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
71.66K
+24.77%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
64.52K
+36.77%
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--

FAQs

Who are the top five shareholders of AC Immune SA?

The top five shareholders of AC Immune SA are: Prof. Dr. Andrea Pfeifer, Ph.D.

How many institutions hold shares of AC Immune SA (ACIU)?

As of 2026Q1, 106 institutions hold shares of AC Immune SA, with a combined market value of approximately 26.78M, accounting for 26.32% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1698579.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.